Research Article

p-Cresyl Sulfate Predicts Ischemic Stroke among Patients on Hemodialysis: A Prospective Cohort Study

Xiao Tan,1 Jianzhou Zou,2 Fangfang Xiang,2 Pan Zhang,3 Bo Shen,2 Yaqiong Wang,2 Xiaoqiang Ding,3,4 and Xuesen Cao2

1Department of Nephrology, Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai, China
2Dialysis Center, Department of Nephrology, Zhongshan Hospital Fudan University, No. 180, Fenglin Road, Shanghai, China
3Shanghai Key Laboratory of Kidney and Blood Purification, No. 180, Fenglin Road, Shanghai, China
4Department of Nephrology, Zhongshan Hospital Fudan University; Shanghai Institute of Kidney and Dialysis, China

Correspondence should be addressed to Xiaoqiang Ding; ding.xiaoqiang@zs-hospital.sh.cn and Xuesen Cao; cxs15339@126.com

Received 17 November 2021; Revised 21 December 2021; Accepted 30 December 2021; Published 31 January 2022

Academic Editor: Paulina Dumnicka

Copyright © 2022 Xiao Tan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background and Purpose. Hemodialysis patients face a higher risk of ischemic stroke. p-Cresyl sulfate is a typical protein-bound uremic toxin that contributes to chronic kidney disease and cardiovascular disease progression, as well as mortality in hemodialysis patients. The present study was aimed at elucidating the association between p-cresyl sulfate and the risk of ischemic stroke in hemodialysis patients. Method. Patients on hemodialysis over 6 months were enrolled in this prospective cohort study and were divided into 2 groups based on plasma p-cresyl sulfate level. The primary end point was the first episode of ischemic stroke during follow-up. The association between p-cresyl sulfate and ischemic stroke incidence was analyzed by Kaplan-Meier method and Cox proportional hazard model. Results. 220 patients were enrolled in this study. 44 patients experienced episodes of first ischemic stroke during follow-up for 87.8 (47.6-119.5) months. Kaplan-Meier analysis demonstrated that the incidence of ischemic stroke in the high p-cresyl sulfate group was significantly higher than that in the low p-cresyl sulfate group (Log-Rank P = 0.007). Cox regression analysis as well proved that p-cresyl sulfate level was significantly associated with the first incidence of ischemic stroke (HR (hazard ratio) 2.332, 95% CI (95% confidence interval) 1.236-4.399, P = 0.009). After being adjusted for other confounding risk factors, the results persisted significant (model 11: HR 2.061, 95% CI 1.030-4.125, P = 0.041). Conclusion. Plasma p-cresyl sulfate predicts the first incidence of ischemic stroke in hemodialysis patients.

1. Introduction

The relationship between kidney diseases and cerebrovascular diseases has become increasingly recognized in recent years. The incidence of cerebrovascular disease is higher among chronic kidney disease (CKD) patients compared to that in the healthy population, and the prevalence of cerebrovascular disease is higher in more advanced stages of CKD [1]. CKD patients, especially end-stage renal disease (ESRD) patients, are with increased hospitalization rates [2, 3] and mortality [4] associated with ischemic stroke.

During CKD progression, uremic toxins accumulate in the circulation since kidney function declines. Among the uremic toxins, protein-bound uremic toxins have recently been noted as a potential link in cardiorenal syndrome [5], and removal of protein-bound uremic toxins by dialysis is extremely difficult due to their high protein-binding affinity [6]. This has been well demonstrated with two of the most typical protein-bound uremic toxins: p-cresyl sulfate (PCS) [7–10] and indoxyl sulfate (IS) [11–13]. Our past research demonstrated that plasma indoxyl sulfate was associated with the first heart failure event in patients on hemodialysis [14]. In this study, we focused on the other protein-bound uremic toxin, PCS.

PCS, with a molecular weight of 188.2 g/mol, originates from sulfation (para-) of the intestinally generated p-cresol, and it is bound to about 95% to the protein albumin in the circulation [15]. In normal condition, the clearance value
of indoxyl sulfate is 1055 ± 148 mL/min/1.73 m², which is 8 ± 1 times of creatinine [16], but it increases significantly in uremic patients (uremic patients 20.9 ± 12.2 μg/mL vs. normal 1.9 ± 1.3 μg/mL) due to renal dysfunction [17]. And plasma levels of PCS were increased with even moderate impairment of renal function [18]. In the past decade, a growing number of publications documented the impact of PCS on CKD progression, cardiovascular diseases, and mortality [7–10, 19]. An existing study also suggests that p-cresyl sulfate is a significant independent predictor of carotid plaque burden [20]. However, the clinical association of PCS and stroke is uncertain. We, therefore, conducted the current prospective study to investigate the relationship between PCS and ischemic stroke in hemodialysis patients.

2. Materials and Methods

2.1. Study Population and Endpoint Evaluation. The study population consisted of 220 patients ≥18 years old, who underwent regular hemodialysis therapy over 6 months in the Blood Purification Center, Zhongshan Hospital, Fudan University. The enrollment was completed within 6 months from July to December 2009. The patients who had heart failure and acute myocardial infarction within 3 months before the study, as well as who had stroke ever, were excluded from our study. Patients were treated thrice weekly (4 hours per session). The study was performed according to the Declaration of Helsinki and approved by the Ethical Committee, Zhongshan Hospital, Fudan University. All participants provided written informed consent.

Ischemic stroke was defined according to ICD-9 diagnosis codes by 2 physicians according to brain imaging (computed tomography and/or magnetic resonance imaging). The primary endpoint was the first incidence of ischemic stroke. The secondary endpoint was death, kidney transplantation, and transfer to other dialysis centers.

2.2. Anthropometric Measurements, Biochemical Measurements, and Clinical Data Collection. Demographic and clinical data includes age, sex, dialysis duration, smoking history, history of medicine application, underlying kidney disease, and comorbidities. Height and weight were measured while patients were without shoes and with light clothes. Body mass index (BMI) was calculated according to the following formula: weight (in kg)/height² (in m²). Blood pressure was defined as the average of all predialysis blood pressure during 4 sessions (12 times in total) before this study. Blood sampling was achieved during a midweek non-dialysis day 8-10 am. Serum blood urea nitrogen (BUN), serum creatinine (Scr), hemoglobin, albumin, pre-albumin, calcium (Ca), phosphorus (P), lipids, uric acid (UA), total homocysteine (tHcy), iron, transferrin, and ferritin were measured via standard methods by the clinical laboratory. The concentrations of high-sensitivity C-reactive protein (hsCRP) and β₂-microglobulin (β₂M) were measured by immunoturbidimetry assay, and the concentration of iPTH (intact parathyroid hormone) was measured by electrochemiluminescence immunoassay.

2.3. PCS Measurement. Standard of PCS (99.8%) was kindly provided by Professor Raymond Vanholder (Ghent University Hospital). Internal standard of warfarin (99.5%) was kindly provided by Shanghai Institute for Drug Control. High-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) method was used to detect PCS concentration in plasma. Briefly, 100 μL plasma was pipetted to a 1.5 mL polypropylene tube. Then, 500 μL of internal standard/protein precipitation solution (50 ng/mL warfarin in methanol) was added to precipitate the proteins. The contents were vortex mixed for 1 min. After centrifugation at 12,000 × g for 10 min, a 100 μL aliquot of clear supernatant was mixed with 100 μL of water in a polypropylene tube and transferred to an autosampler. A volume of 5 μL was injected into LC-MS/MS. The chromatographic separation was achieved on a Venusil XBP Phenyl column (100 mm × 2.1 mm, 5 μm; Bonna-Agela Technologies Inc, Wilmington, DE, USA). Mobile phase A was 2 mmol/L ammonium acetate in 0.1% formic acid (v/v). Mobile B was methanol. The mobile phase (A : B = 30 : 70) was delivered at a flow rate of 0.35 mL/min. The temperature of the column and autosampler was maintained at 40°C and 4°C, respectively. Mass spectrometric detection was performed on an API 3000 triple quadrupole instrument (Applied Biosystems, Toronto, ON, Canada) in multiple reaction monitoring (MRM) mode. A TurboI onSpray ionization (ESI) interface in negative ionization mode was used. Turbo spray voltage was set at -4200 V. Source temperature was maintained at 500°C. The compound parameters, collision energy (CE), declustering potential (DP), entrance potential (EP), and collision exit potential (CXP) were -27 V, -30 V, -10 V, and -15 V for PCS and -20 V, -46 V, -10 V, and -15 V for warfarin. Quadrupole 1 and quadrupole 3 were maintained at unit resolution. Dwelling time set was 200 ms for all the analytes. Mass transitions m/z187.1 — 107.1 for PCS and m/z307.0 — 249.7 for warfarin were used. Data processing was performed with Analyst 1.4.1 software package (Applied Biosystems, Toronto, ON, Canada). Standard curve for IS was set at 0.025, 0.05, 0.1, 0.5, 1, 5, 10, and 40 μg/mL with an average r value of 0.999 (n = 8). The lower limit of quantitation was 0.025 μg/mL. Data analysis was performed with Analyst 1.4.1 software package (Applied Biosystems, Toronto, ON, Canada).

2.4. Statistical Analyses. For the primary endpoint, the Kaplan-Meier method and Cox proportional hazard model were used to evaluate the association between PCS and the first incidence of ischemic stroke. To adjust confounding risk factors, we constructed Model 1 (age, sex, and BMI), Model 2 (hemoglobin, iron, transferrin, and ferritin), Model 3 (history of smoking, primary hypertension, coronary heart disease, diabetes, and urarthritis), Model 4 (systolic blood pressure (SBP), diastolic blood pressure (DBP), urinary volume, and single-pool Kt/V (spKt/V)), Model 5 (albumin, prealbumin, BUN, Scr, UA, and glucose), Model 6 (triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A (Apo-A), apolipoprotein B.
Table 1: Baseline demographic, clinical, and biochemical characteristics.

|                               | All patients (n = 220) | Low-PCS group (PCS ≤ 20.10 μg/mL) (n = 110) | High-PCS group (PCS > 20.10 μg/mL) (n = 110) | P     |
|-------------------------------|------------------------|----------------------------------------------|----------------------------------------------|-------|
| Age (year)                    | 56 ± 14                | 55 ± 13                                      | 57 ± 16                                      | 0.093 |
| Sex (M/F)                     | 125/95                 | 59/51                                        | 66/44                                        | 0.207 |
| Height (m)                    | 1.56 ± 0.09            | 1.64 ± 0.09                                  | 1.65 ± 0.09                                  | 0.973 |
| Weight (kg)                   | 58.7 (52.0, 66.2)      | 57.6 (52.3, 65.6)                            | 60.3 (48.8, 69.3)                            | 0.799 |
| BMI (kg/m²)                   | 21.8 (19.9, 24.0)      | 21.8 (20.0, 23.7)                            | 21.7 (19.2, 24.0)                            | 0.595 |
| SBP (mmHg)                    | 136 ± 17               | 136 ± 17                                     | 137 ± 17                                     | 0.656 |
| DBP (mmHg)                    | 82 ± 10                | 83 ± 10                                      | 82 ± 10                                      | 0.295 |
| spKt/V                         | 1.34 (1.17, 1.59)      | 1.33 (1.10, 1.53)                            | 1.36 (1.20, 1.66)                            | 0.011 |
| Urinary volume (mL/kg/24 h)   | 0 (0, 5.80)            | 0 (0, 5.60)                                  | 1.09 (0, 5.93)                               | 0.596 |
| Smoking history (%)           | 36.4                   | 28.2                                         | 44.5                                         | 0.017 |
| Underlying kidney disease     |                        |                                              |                                              | 0.359 |
| Glomerular disease (%)        | 44.1                   | 40.9                                         | 47.3                                         |       |
| Diabetic nephropathy (%)      | 7.3                    | 7.3                                          | 7.3                                          |       |
| Hypertensive nephropathy (%)  | 7.3                    | 8.2                                          | 6.4                                          |       |
| Polycystic kidney disease (%) | 6.8                    | 10                                           | 3.6                                          |       |
| Medicinal nephropathy (%)     | 4.5                    | 6.4                                          | 2.7                                          |       |
| Others (%)                    | 12.3                   | 10.9                                         | 13.6                                         |       |
| Unknown (%)                   | 17.7                   | 16.4                                         | 19.1                                         |       |
| Comorbidity                   |                        |                                              |                                              |       |
| Primary hypertension (%)      | 27.7                   | 26.4                                         | 29.1                                         | 0.382 |
| CHD (%)                       | 5.9                    | 3.6                                          | 8.2                                          | 0.126 |
| Diabetes (%)                  | 11.4                   | 8.2                                          | 14.5                                         | 0.101 |
| Uarthritis (%)                | 22.7                   | 24.5                                         | 20.9                                         | 0.315 |
| Medications                   |                        |                                              |                                              |       |
| CCB (%)                       | 62.3                   | 64.5                                         | 60                                           | 0.289 |
| ACEI (%)                      | 15.9                   | 12.7                                         | 19.1                                         | 0.134 |
| ARB (%)                       | 26.8                   | 33.6                                         | 20.0                                         | 0.033 |
| β-Blocker (%)                 | 17.3                   | 20                                           | 14.5                                         | 0.186 |
| α-Blocker (%)                 | 20.0                   | 21.8                                         | 18.2                                         | 0.307 |
| Aspirin (%)                   | 20.5                   | 20                                           | 21.0                                         | 0.514 |
| Statin (%)                    | 5.9                    | 5.5                                          | 6.4                                          | 0.500 |
| Calcium (%)                   | 67.3                   | 70.0                                         | 64.5                                         | 0.236 |
| 1,25(OH)₂vitD₃ (%)            | 54.5                   | 62.7                                         | 46.4                                         | 0.011 |
| Albumin (g/L)                 | 40 (37, 42)            | 39 (36, 41)                                  | 40 (38, 42)                                  | 0.010 |
| Prealbumin (g/L)              | 0.34 ± 0.08            | 0.33 ± 0.08                                  | 0.35 ± 0.08                                  | 0.736 |
| Hemoglobin (g/L)              | 104 (96, 113)          | 104 (94, 112)                                | 106 (97, 114)                                | 0.258 |
| Iron (μmol/L)                 | 10.8 (7.8, 15.0)       | 10.6 (6.8, 14.7)                             | 11.3 (8.5, 15.5)                             | 0.070 |
| Transferrin (g/L)             | 1.90 (1.65, 2.15)      | 1.89 (1.66, 2.19)                            | 1.93 (1.64, 2.12)                            | 0.859 |
| Ferritin (ng/mL)              | 121 (68.8, 260.7)      | 113.0 (61.3, 263.6)                          | 126.2 (68.9, 258.1)                          | 0.724 |
| BUN (mmol/L)                  | 23.9 ± 5.3             | 23.2 ± 5.0                                   | 24.5 ± 5.6                                   | 0.275 |
| SCr (μmol/L)                  | 1004 (863, 1206)       | 980 (855, 1113)                              | 1030 (887, 1273)                             | 0.042 |
| UA (μmol/L)                   | 433 (382, 494)         | 428 (382, 483)                               | 439 (377, 500)                               | 0.530 |
| Glucose (mmol/L)              | 5.4 (4.4, 6.7)         | 5.5 (4.4, 6.7)                               | 5.3 (4.4, 6.8)                               | 0.841 |
| 25OHvitD (nmol/L)             | 57.3 ± 18.9            | 56.1 ± 19.3                                  | 58.4 ± 18.5                                  | 0.578 |
| Ca (mmol/L)                   | 2.20 ± 0.21            | 2.20 ± 0.21                                  | 2.22 ± 0.21                                  | 0.866 |
| P (mmol/L)                    | 2.17 ± 0.63            | 2.27 ± 0.62                                  | 2.06 ± 0.63                                  | 0.689 |
Table 1: Continued.

|                                | All patients (n = 220) | Low-PCS group (PCS ≤ 20.10 μg/mL) (n = 110) | High-PCS group (PCS > 20.10 μg/mL) (n = 110) | P       |
|--------------------------------|------------------------|---------------------------------------------|---------------------------------------------|---------|
| iPTH (pg/mL)                   | 276.9 (136.9, 559.4)   | 289.3 (144.3, 587.5)                        | 270.1 (136.7, 518.8)                        | 0.274   |
| hsCRP (mg/L)                   | 2.0 (0.7, 6.1)         | 2.8 (0.7, 9.0)                              | 1.4 (0.7, 4.3)                              | 0.038   |
| TG (mmol/L)                    | 1.44 (1.08, 1.98)      | 1.36 (1.07, 1.90)                           | 1.46 (1.08, 2.01)                           | 0.510   |
| TC (mmol/L)                    | 4.25 (3.72, 5.00)      | 4.16 (3.70, 4.86)                           | 4.33 (3.72, 5.26)                           | 0.420   |
| HDL-C (mmol/L)                 | 1.10 (0.89, 1.37)      | 1.11 (0.92, 1.39)                           | 1.06 (0.86, 1.35)                           | 0.216   |
| LDL-C (mmol/L)                 | 2.42 (1.87, 2.95)      | 2.40 (1.89, 2.90)                           | 2.45 (1.86, 3.09)                           | 0.594   |
| Apo-A (g/L)                    | 1.18 (1.02, 1.40)      | 1.22 (1.03, 1.44)                           | 1.15 (1.01, 1.35)                           | 0.172   |
| Apo-B (g/L)                    | 0.81 (0.69, 0.98)      | 0.80 (0.69, 0.98)                           | 0.83 (0.69, 0.99)                           | 0.578   |
| Lp(a) (mg/L)                   | 175.5 (114.0, 280.8)   | 175.0 (121.0, 302.5)                        | 175.5 (109.8, 273.3)                        | 0.716   |
| tHcy (µmol/L)                  | 35.4 (28.0, 45.7)      | 33.3 (27.2, 44.8)                           | 36.8 (30.3, 45.9)                           | 0.074   |
| β2M (mg/L)                     | 36.1 (30.3, 42.7)      | 36.4 (30.2, 43.1)                           | 35.6 (30.6, 41.6)                           | 0.593   |
| NT-proBNP (ng/mL)              | 3807 (1747, 8816)      | 3696 (1379, 10352)                          | 4097 (1991, 7917)                           | 0.601   |
| LVMI (g/m²)                    | 108.2 (90.6, 137.8)    | 110.1 (90.4, 141.7)                         | 106.8 (90.8, 129.1)                         | 0.529   |
| LVEF (%)                       | 67 (62, 72)            | 68 (63, 73)                                 | 66 (62, 70)                                 | 0.158   |
| PCS (µg/mL)                    | 22.52 ± 16.22          | 9.53 ± 5.38                                | 35.53 ± 12.60                               | < 0.001 |

Abbreviations: BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; spKt/V: single-pool Kt/V; CHD: coronary heart disease; CCB: calcium channel blocker; ACEI: angiotensin conversion enzyme inhibitor; ARB: angiotensin receptor blocker; BUN: blood urea nitrogen; SCr: serum creatinine; UA: uric acid; ALP: alkaline phosphatase; Ca: calcium; P: phosphorus; Ca×P: calcium phosphorus product; iPTH: intact parathyroid hormone; hsCRP: high-sensitivity C-reactive protein; TG: triglyceride; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Apo-A: apolipoprotein A; Apo-B: apolipoprotein B; Lp(a): lipoprotein (a); tHcy: total homocysteine; β2M: β2-microglobulin; PCS: p-cresyl sulfate.

(Apo-B), and tHcy), Model 7 (Ca, P, iPTH, and 25 hydroxy vitamin D (25OHD3)), Model 8 (hsCRP and β2M), Model 9 (history of taking calcium channel entry blockers (CCB), angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), β-blocker, α-blocker, aspirin, statin, calcium-based phosphate binders, and 1,25(OH)2vitD3), Model 10 (N-terminal probrain natriuretic peptide (NT-proBNP), Left Ventricular Mass Index (LVMI), and left ventricular ejection fraction (LVEF)), and Model 11. The criterion for Model 11 selection was determined as P < 0.05 in the univariate Cox proportional hazard model. PCS was entered as a dichotomous variable.

All data were expressed as mean ± SD, median (or interquartile range), or frequency, as appropriate. To compare the two groups of normal data, an independent samples t-test was conducted. A two-tailed P < 0.05 was considered statistically significant. All data analyses were performed via SPSS 22.0 (SPSS Inc., Chicago, IL, USA).

### 3. Results

#### 3.1. Baseline Characteristics of the Study Population

The baseline characteristics of the patients are listed in Table 1. The cohort consisted of 220 hemodialysis patients (125 males), with an age of 56 ± 14 years. Glomerular disease was the leading cause of end-stage renal disease, accounting for 44.1%. The prevalence of primary hypertension, CHD (coronary heart disease), diabetes, and arthralgia was 27.7%, 5.9%, 11.4%, and 22.7%, respectively. According to the plasma PCS concentration, patients were categorized into two groups: low-PCS group (PCS ≤ 20.10 μg/mL) and high-PCS group (PCS > 20.10 μg/mL). Compared with the low-PCS group, patients in the high-PCS group had lower serum 25(OH)D and 1,25(OH)2D3 medication rate and lower serum hsCRP (high-sensitivity C-reactive protein), as well as higher serum albumin and creatine. There were no significant differences in other characteristics (Table 1).

Median follow-up time was 87.8 (47.6-119.5) months. During follow-up, 44 patients experienced episodes of ischemic stroke, and 5 of which were followed by cerebral hemorrhage. 10 patients had acute myocardial infarction. 16 patients were lost to follow-up because of transfer to a different center. 15 patients received kidney transplantation. 101 patients died, of which 9 were classified as death caused by ischemic stroke, 6 as death caused by cerebral hemorrhage, and 25 as cardiac death.

#### 3.2. Association between Serum p-Cresyl Sulfate Level and Ischemic Stroke

In this study, 44 patients experienced the first incidence of ischemic stroke. In the crude analysis by the Kaplan-Meier method, we found that the incidence of...
ischemic stroke in the high-PCS group was significantly higher than that in the low-PCS group (Log-Rank $P = 0.007$) (Figure 1).

In the univariate Cox proportional hazard model, PCS was entered only as a dichotomous variable. Results showed that PCS was significantly associated with first cerebral infarction (HR 2.332, 95% CI 1.236-4.399, $P = 0.009$) (Figure 2). A series of models were constructed to adjust confounding risk factors, including Models 1-11. PCS was still significant in Models 1-10 (Table 2). In Model 11 (hierarchically selected covariates of age, serum prealbumin, SCr, serum glucose, history of primary hypertension, history of coronary heart disease, history of diabetes, and history of taking calcium-based phosphate binders), result still remained significant after adjustment for confounding risk factors listed above (HR 2.061, 95% CI 1.030-4.125, $P = 0.041$) (Table 3). In Model 11, age, history of diabetes, and history of taking calcium-based phosphate binders as well are associated with ischemic stroke after adjustment of other confounding risk factors (Table 3).

**4. Discussion**

Hemodialysis patients face a higher risk and poorer outcomes of ischemic stroke, due to special risk factors in this particular population. However, stroke prevention measures in patients on dialysis remain similar to those in general population, and treatment options for reducing ischemic stroke in hemodialysis patients remain limited. It is critical to identify particular risk factors for stroke in ESRD, to develop novel prevention measures and treatment strategies.

In this prospective cohort study, we found that a protein-bound uremic toxin, p-cresyl sulfate, predicts the incidence of newly developed ischemic stroke in hemodialysis patients. PCS is a kind of protein-bound uremic toxin originating from intestinally generated p-cresol. Existing studies focused on the relationship between serum PCS level and mortality, especially cardiovascular mortality in the hemodialysis [7, 21] and CKD patients [10, 22]. Our study innovatively provided evidence for an association between higher serum PCS level and an increased risk of ischemic stroke in hemodialysis patients. Result still remained significant after adjustment for other risk factors, suggesting that PCS is independently associated with the first incidence of ischemic stroke in hemodialysis patients.

Endothelial dysfunction is one possible explanation for the association between high serum PCS level and an increased risk of ischemic stroke in hemodialysis patients. Meijers et al. [23] found that serum p-cresol concentration is independently associated with the number of circulating EMPs (endothelial microparticles, surrogate biomarkers for endothelial dysfunction, and also could be biomarkers of ischemic [24] and hemorrhagic [25] stroke) in hemodialysis patients, and PCS induces EMP shedding in vitro. Cell experiments demonstrated that PCS activates leucocyte [26], human vascular smooth muscle cells, and human umbilical vein endothelial cell [27] free radical production, promoting both vascular dysfunction and vascular remodeling. PCS also exerts proinflammatory effects that contribute to vascular damage by motivating the crosstalk between leukocytes and vessels [28]. Endothelial damage is an essential cause of ischemic stroke. Once the endothelium is impaired, arterial smooth muscle cells proliferate and lead
to further contraction of the vessel lumen. Mast cells release elastase and metalloproteinases, contributing to eventual plaque rupture and stroke [29]. Endothelium injury plays important roles in the development of cerebral hemorrhage. Brain endothelial cells function in the maintenance of the blood–brain barrier [30], of which integrity disrupts during and after hemorrhage. Endothelial cells also participate in the delayed phase of hemorrhage, including cerebral vasospasm, microthrombosis, and inflammation, affecting its prognosis [31].
We also identified other risk factors for stroke besides serum PCS level, including age, history of diabetes, and history of taking calcium-based phosphate binders. Diabetes mellitus is a risk factor for stroke in the general population [32]; our result suggests that diabetes may also be a risk factor of ischemic stroke in hemodialysis patients. Calcium-based phosphate binders are widely used in hemodialysis patients with hyperphosphatemia [33]. Although there are few clinical evidences indicating that calcium load directly leads to vascular calcification, a clinical trial suggests that non-calcium-containing phosphate binder such as sevelamer may contribute to lower vascular calcification compared with calcium-containing binders [34]. However, in the year of 2009, non-calcium-containing phosphate binders were not used in our center.

Our study has several strengths, including long follow-up time, prospectively collected data, and that a series of possible confounders were adjusted for. Many studies suggest that PCS contributes to endothelial damage and vascular remodeling, while no clinical evidence ever demonstrated the association between PCS and stroke. Our study first demonstrated that PCS is associated with the first incidence of ischemic stroke. The limitation of our study is that a single time point of serum PCS measurement may not appropriately describe intraindividual variability in levels over time and thus may lead to misclassification of patients into appropriate categories.

5. Conclusions

In summary, we demonstrated that high plasma PCS level was associated with higher risk of first incidence of ischemic stroke in hemodialysis patients. Our finding was independent of a series of conventional and unconventional risk factors. Our results suggest that PCS may be an important biomarker to predict ischemic stroke in a hemodialysis population.

Data Availability

Data used during the study are available from the corresponding author by request.

Table 3: Multivariate Cox for the incidence of first ischemic stroke (Model 11).

| Variables                  | Univariate P | HR  | Multivariate analysis 95% CI | P  |
|----------------------------|--------------|-----|-----------------------------|----|
| Age                        | <0.001       | 1.051 | 1.019-1.084                | 0.002 |
| SCr                        | 0.004        | 1.000 | 0.998-1.001                | 0.829 |
| Glucose                    | 0.036        | 1.006 | 0.998-1.001                | 0.976 |
| Prealbumin                 | 0.023        | 0.976 | 0.937-1.017                | 0.255 |
| History of primary hypertension | 0.010     | 0.990 | 0.479-2.045                | 0.978 |
| History of coronary heart disease | <0.001    | 1.872 | 0.721-4.861                | 0.198 |
| History of diabetes       | <0.001       | 2.733 | 1.221-6.120                | 0.015 |
| History of taking calcium  | 0.001        | 0.440 | 0.237-0.818                | 0.010 |
| PCS                        | 0.009        | 2.061 | 1.030-4.125                | 0.041 |

Abbreviations: SCr: serum creatinine; PCS: p-cresyl sulfate.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Xiaojiang Ding and Xuesen Cao contributed equally to this study.

Acknowledgments

Standard of PCS (99.8%) was kindly provided by Professor Raymond Vanholder (Ghent University Hospital). This work was supported by the Clinical Foundation of Zhongshan Hospital Affiliated to Fudan University (2020ZSLC09), Shanghai Most Important Clinical Medical Center and Key Discipline Construction Program (2017ZZ01015), and Shanghai Key Laboratory of Kidney and Blood Purification (Grant No. 20DZ2271600).

References

[1] K. Toyoda and T. Ninomiya, “Stroke and cerebrovascular diseases in patients with chronic kidney disease,” Lancet Neurology, vol. 13, pp. 823–833, 2014.
[2] H. H. Wang, S. Y. Hung, J. M. Sung, K. Y. Hung, and J. D. Wang, “Risk of stroke in long-term dialysis patients compared with the general population,” American Journal of Kidney Diseases, vol. 63, pp. 604–611, 2014.
[3] P. Masson, P. J. Kelly, J. C. Craig, R. I. Lindley, and A. C. Webster, “Risk of stroke in patients with ESRD,” Clinical Journal of the American Society of Nephrology, vol. 10, pp. 1585–1592, 2015.
[4] J. B. Wetmore, M. A. Phadnis, E. F. Ellerbeck, T. I. Shireman, S. K. Rigler, and J. D. Mahnkopf, “Relationship between stroke and mortality in dialysis patients,” Clinical Journal of the American Society of Nephrology, vol. 10, pp. 80–89, 2015.
[5] S. Lekawanvijit, A. R. Kompa, and H. Krum, “Protein-bound uremic toxins: a long overlooked culprit in cardiorenal syndrome,” American Journal of Physiology. Renal Physiology, vol. 311, pp. F52–F62, 2016.
[6] Y. Itoh, A. Ezawa, K. Kikuchi, Y. Tsuruta, and T. Niwa, “Protein-bound uremic toxins in hemodialysis patients measured
by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production,” Analytical and Bioanalytical Chemistry, vol. 403, pp. 1841–1850, 2012.

[7] I. W. Wu, K. H. Hsu, H. J. Hsu et al., “Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients—a prospective cohort study,” Nephrology, Dialysis, Transplantation, vol. 27. pp. 1169–1175, 2012.

[8] C. H. Wang, M. L. Cheng, M. H. Liu et al., “Increased p-cresyl sulfate level is independently associated with poor outcomes in patients with heart failure,” Heart and Vessels, vol. 31, pp. 1100–1108, 2016.

[9] R. Poesen, L. Viaene, K. Verbeke et al., “Cardiovascular disease relates to intestinal uptake of p-cresol in patients with chronic kidney disease,” BMC Nephrology, vol. 15, no. 1, p. 87, 2014.

[10] C. J. Lin, C. F. Pan, C. K. Chuang et al., “P-cresyl sulfate is a valuable predictor of clinical outcomes in pre-ESRD patients,” BioMed Research International, vol. 2014, Article ID 526932, 2014.

[11] X. Tan, X. Cao, J. Zou et al., “Indoxyl sulfate, a valuable biomarker in chronic kidney disease and dialysis,” Hemodialysis International, vol. 21, pp. 161–167, 2017.

[12] C. J. Lin, H. L. Liu, C. F. Pan et al., “Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease,” Archives of Medical Research, vol. 43, pp. 451–456, 2012.

[13] M. Yu, Y. J. Kim, and D. H. Kang, “Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress,” Clinical Journal of the American Society of Nephrology, vol. 6, pp. 30–39, 2011.

[14] X. S. Cao, J. Chen, J. Z. Zou et al., “Association of indoxyl sulfate with heart failure among patients on hemodialysis,” Clinical Journal of the American Society of Nephrology, vol. 10, pp. 111–119, 2015.

[15] T. Gryp, R. Vanholder, M. Vaneechoutte, and G. Glorieux, “p-Cresyl sulfate,” Toxins (Basel), vol. 9, 2017.

[16] T. L. Sirich, P. A. Aronov, N. S. Plummer, T. H. Hostetter, and T. W. Meyer, “Numerous protein-bound solutes are cleared by the kidney with high efficiency,” Kidney International, vol. 84, pp. 585–590, 2013.

[17] F. Duranton, G. Cohen, R. De Smet et al., “Normal and pathologic concentrations of uremic toxins,” J AM SOC NEPHROL., vol. 23, no. 7, pp. 1258–1270, 2012.

[18] M. Pignanelli, C. Bogiatzi, G. Gloor et al., “Moderate renal impairment and toxic metabolites produced by the intestinal microbiome: dietary implications,” Journal of Renal Nutrition, vol. 29, pp. 55–64, 2019.

[19] I. W. Wu, K. H. Hsu, C. C. Lee et al., “p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease,” Nephrology, Dialysis, Transplantation, vol. 26, pp. 938–947, 2011.

[20] C. Bogiatzi, G. Gloor, E. Allen-Vercoe et al., “Metabolic products of the intestinal microbiome and extremes of atherosclerosis,” Atherosclerosis, vol. 273, pp. 91–97, 2018.

[21] B. Bammens, P. Evenepoel, H. Keuleers, K. Verbeke, and Y. Vanrenterghem, “Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients,” Kidney International, vol. 69, pp. 1081–1087, 2006.

[22] S. Liabeuf, D. V. Barreto, F. C. Barreto et al., “Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease,” Nephrology, Dialysis, Transplantation, vol. 25, no. 4, pp. 1183–1191, 2010.

[23] B. K. Meijers, S. Van Kerckhoven, K. Verbeke et al., “The Uremic Retention Solute p-Cresyl Sulfate and Markers of Endothelial Damage,” American Journal of Kidney Diseases, vol. 54, no. 5, pp. 891–901, 2009.

[24] G. Chiva-Blanch, R. Suades, J. Crespo et al., “Microparticle shedding from neural progenitor cells and vascular compartment cells is increased in ischemic stroke,” PLoS One, vol. 11, no. 1, article ???, 2016.

[25] P. Lackner, A. Dietmann, R. Beer et al., “Cellular microparticles as a marker for cerebral vasospasm in spontaneous subarachnoid hemorrhage,” Stroke, vol. 41, pp. 2353–2357, 2010.

[26] E. Schepers, N. Meert, G. Glorieux, J. Goeman, J. Van der Eycken, and R. Vanholder, “P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production,” Nephrology, Dialysis, Transplantation, vol. 22, no. 2, pp. 592–596, 2006.

[27] P. Gross, Z. A. Massy, L. Henaut et al., “Para-cresyl sulfate acutely impairs vascular reactivity and induces vascular remodeling,” Journal of Cellular Physiology, vol. 230, pp. 2927–2935, 2015.

[28] A. Pletinck, G. Glorieux, E. Schepers et al., “Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall,” J AM SOC NERPHROL., vol. 24, pp. 1981–1994, 2013.

[29] J. A. Madden, “Role of the vascular endothelium and plaque in acute ischemic stroke,” Neurology, vol. 79, pp. 588–582, 2012.

[30] B. Engelhardt and S. Liebner, “Novel insights into the development and maintenance of the blood-brain barrier,” Cell and Tissue Research, vol. 355, pp. 687–699, 2014.

[31] K. T. Peeyush, D. W. McBride, P. K. Dash, K. Matsumura, A. Rubi, and S. L. Blackburn, “Calcium-based phosphate binders on coronary artery calcification and injury in subarachnoid hemorrhage,” Molecular Neurobiology, vol. 56, no. 3, pp. 1992–2006, 2019.

[32] S. A. Peters, R. R. Huxley, and M. Woodward, “Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775 385 individuals and 12 539 strokes,” Lancet, vol. 383, no. 9933, pp. 1973–1980, 2014.

[33] S. R. Taksande and E. M. Worcester, “Calcium supplementation in chronic kidney disease,” Expert Opinion on Drug Safety, vol. 13, pp. 1175–1185, 2014.

[34] T. Kakuta, R. Tanaka, T. Hyodo et al., “Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients,” American Journal of Kidney Diseases, vol. 57, pp. 422–431, 2011.